Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.

<h4>Background</h4>Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors.<h4>Objective</h4>Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT fa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Franziska Ruëff, Bernhard Przybilla, Maria Beatrice Biló, Ulrich Müller, Fabian Scheipl, Michael J Seitz, Werner Aberer, Anna Bodzenta-Lukaszyk, Floriano Bonifazi, Paolo Campi, Ulf Darsow, Gabrielle Haeberli, Thomas Hawranek, Helmut Küchenhoff, Roland Lang, Oliviero Quercia, Norbert Reider, Peter Schmid-Grendelmeier, Maurizio Severino, Gunter Johannes Sturm, Regina Treudler, Brunello Wüthrich
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2013
Materias:
R
Q
Acceso en línea:https://doaj.org/article/7709054fbdf8482ab097bfe1348c071a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7709054fbdf8482ab097bfe1348c071a
record_format dspace
spelling oai:doaj.org-article:7709054fbdf8482ab097bfe1348c071a2021-11-18T07:45:12ZClinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.1932-620310.1371/journal.pone.0063233https://doaj.org/article/7709054fbdf8482ab097bfe1348c071a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23700415/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors.<h4>Objective</h4>Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT failure during the maintenance phase.<h4>Methods</h4>In this observational prospective multicenter study, we followed 357 patients with established honey bee or vespid venom allergy after the maintenance dose of VIT had been reached. In all patients, VIT effectiveness was either verified by sting challenge (n = 154) or patient self-reporting of the outcome of a field sting (n = 203). Data were collected on BTC, age, gender, preventive use of anti-allergic drugs (oral antihistamines and/or corticosteroids) right after a field sting, venom dose, antihypertensive medication, type of venom, side effects during VIT, severity of index sting reaction preceding VIT, and duration of VIT. Relative rates were calculated with generalized additive models.<h4>Results</h4>22 patients (6.2%) developed generalized symptoms during sting challenge or after a field sting. A strong association between the frequency of VIT failure and BTC could be excluded. Due to wide confidence bands, however, weaker effects (odds ratios <3) of BTC were still possible, and were also suggested by a selective analysis of patients who had a sting challenge. The most important factor associated with VIT failure was a honey bee venom allergy. Preventive use of anti-allergic drugs may be associated with a higher protection rate.<h4>Interpretation</h4>It is unlikely that an elevated BTC has a strong negative effect on the rate of treatment failures. The magnitude of the latter, however, may depend on the method of effectiveness assessment. Failure rate is higher in patients suffering from bee venom allergy.Franziska RuëffBernhard PrzybillaMaria Beatrice BilóUlrich MüllerFabian ScheiplMichael J SeitzWerner AbererAnna Bodzenta-LukaszykFloriano BonifaziPaolo CampiUlf DarsowGabrielle HaeberliThomas HawranekHelmut KüchenhoffRoland LangOliviero QuerciaNorbert ReiderPeter Schmid-GrendelmeierMaurizio SeverinoGunter Johannes SturmRegina TreudlerBrunello WüthrichPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e63233 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Franziska Ruëff
Bernhard Przybilla
Maria Beatrice Biló
Ulrich Müller
Fabian Scheipl
Michael J Seitz
Werner Aberer
Anna Bodzenta-Lukaszyk
Floriano Bonifazi
Paolo Campi
Ulf Darsow
Gabrielle Haeberli
Thomas Hawranek
Helmut Küchenhoff
Roland Lang
Oliviero Quercia
Norbert Reider
Peter Schmid-Grendelmeier
Maurizio Severino
Gunter Johannes Sturm
Regina Treudler
Brunello Wüthrich
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
description <h4>Background</h4>Treatment failure during venom immunotherapy (VIT) may be associated with a variety of risk factors.<h4>Objective</h4>Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters with the frequency of VIT failure during the maintenance phase.<h4>Methods</h4>In this observational prospective multicenter study, we followed 357 patients with established honey bee or vespid venom allergy after the maintenance dose of VIT had been reached. In all patients, VIT effectiveness was either verified by sting challenge (n = 154) or patient self-reporting of the outcome of a field sting (n = 203). Data were collected on BTC, age, gender, preventive use of anti-allergic drugs (oral antihistamines and/or corticosteroids) right after a field sting, venom dose, antihypertensive medication, type of venom, side effects during VIT, severity of index sting reaction preceding VIT, and duration of VIT. Relative rates were calculated with generalized additive models.<h4>Results</h4>22 patients (6.2%) developed generalized symptoms during sting challenge or after a field sting. A strong association between the frequency of VIT failure and BTC could be excluded. Due to wide confidence bands, however, weaker effects (odds ratios <3) of BTC were still possible, and were also suggested by a selective analysis of patients who had a sting challenge. The most important factor associated with VIT failure was a honey bee venom allergy. Preventive use of anti-allergic drugs may be associated with a higher protection rate.<h4>Interpretation</h4>It is unlikely that an elevated BTC has a strong negative effect on the rate of treatment failures. The magnitude of the latter, however, may depend on the method of effectiveness assessment. Failure rate is higher in patients suffering from bee venom allergy.
format article
author Franziska Ruëff
Bernhard Przybilla
Maria Beatrice Biló
Ulrich Müller
Fabian Scheipl
Michael J Seitz
Werner Aberer
Anna Bodzenta-Lukaszyk
Floriano Bonifazi
Paolo Campi
Ulf Darsow
Gabrielle Haeberli
Thomas Hawranek
Helmut Küchenhoff
Roland Lang
Oliviero Quercia
Norbert Reider
Peter Schmid-Grendelmeier
Maurizio Severino
Gunter Johannes Sturm
Regina Treudler
Brunello Wüthrich
author_facet Franziska Ruëff
Bernhard Przybilla
Maria Beatrice Biló
Ulrich Müller
Fabian Scheipl
Michael J Seitz
Werner Aberer
Anna Bodzenta-Lukaszyk
Floriano Bonifazi
Paolo Campi
Ulf Darsow
Gabrielle Haeberli
Thomas Hawranek
Helmut Küchenhoff
Roland Lang
Oliviero Quercia
Norbert Reider
Peter Schmid-Grendelmeier
Maurizio Severino
Gunter Johannes Sturm
Regina Treudler
Brunello Wüthrich
author_sort Franziska Ruëff
title Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
title_short Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
title_full Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
title_fullStr Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
title_full_unstemmed Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
title_sort clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the european academy of allergology and clinical immunology interest group on insect venom hypersensitivity.
publisher Public Library of Science (PLoS)
publishDate 2013
url https://doaj.org/article/7709054fbdf8482ab097bfe1348c071a
work_keys_str_mv AT franziskarueff clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT bernhardprzybilla clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT mariabeatricebilo clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT ulrichmuller clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT fabianscheipl clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT michaeljseitz clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT werneraberer clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT annabodzentalukaszyk clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT florianobonifazi clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT paolocampi clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT ulfdarsow clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT gabriellehaeberli clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT thomashawranek clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT helmutkuchenhoff clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT rolandlang clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT olivieroquercia clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT norbertreider clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT peterschmidgrendelmeier clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT maurizioseverino clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT gunterjohannessturm clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT reginatreudler clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
AT brunellowuthrich clinicaleffectivenessofhymenopteravenomimmunotherapyaprospectiveobservationalmulticenterstudyoftheeuropeanacademyofallergologyandclinicalimmunologyinterestgrouponinsectvenomhypersensitivity
_version_ 1718423044151574528